Dr. DeMesa and Ms. Sanford recently received a Wells Notice from the Securities and Exchange Commission, which stated that the commission made preliminary determinations to recommend that it file enforcement actions against the company, Dr. DeMesa, and Ms. Sanford, alleging violations of the anti-fraud provisions of federal securities laws.
Board Chair Jim Heppell said the alleged violations do not relate to the Company’s technology or intellectual property.
“The Board believes that Emerald’s unique technology has significant merit and value, and the Company is committed to developing its novel therapeutic candidates to potentially address diseases with unmet needs,” Mr. Heppell said.
Emeralds Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
